BACKGROUND: The population of cancer survivors is rapidly growing in the United States. Long-term and late effects of cancer, combined with the ongoing management of other chronic conditions, make survivors particularly vulnerable to polypharmacy and its adverse effects. In the current study, the authors examined patterns of prescription medication use and polypharmacy in a population-based sample of cancer survivors. METHODS: Using data from the Medical Expenditure Panel Survey (MEPS), the authors matched cancer survivors (5216 survivors) with noncancer controls (19,588 controls) by age, sex, and survey year. Polypharmacy was defined as 5 unique medications. The authors estimated the percentage of respondents prescribed medications within therapeutic classes and total prescription expenditures. RESULTS: A higher percentage of cancer survivors were prescribed 5 unique medications (64.0%; 95% confidence interval [95% CI], 62.3%-65.8%) compared with noncancer controls (51.5%; 95% CI, 50.4%-52.6%), including drugs with abuse potential. Across all therapeutic classes, a higher percentage of newly (1 year since diagnosis) and previously (>1 years since diagnosis) diagnosed survivors were prescribed medications compared with controls, with large differences observed with regard to central nervous system agents (65.8% [95% CI, 62.3%-69.3%] vs 57.4% [95% CI, 55.3%-59.5%] vs 46.0% [95% CI, 45.0%-46.9%]). Specifically, nearly 10% of survivors were prescribed benzodiazepines and/or opioids compared with approximately 5% of controls. Survivors had more than double the prescription expenditures (median of $1633 vs $784 among controls). Findings persisted across age and comorbidity categories. CONCLUSIONS: Cancer survivors were prescribed a higher number of unique medications, including drugs with abuse potential, thereby increasing their risk of adverse drug events, financial toxicity, poor adherence, and drug-drug interactions.
INTRODUCTION
With advances in early detection and treatment and increases in life expectancy, the population of cancer survivors in the United States is predicted to reach 26.1 million by 2040. 1 Nearly one-half of cancer survivors have lived 10 years beyond their diagnosis, and two-thirds have lived beyond 5 years. 2 Survivors have complex health needs. 3, 4 Nearly 70% of individuals living with cancer have other chronic conditions (eg, diabetes, cardiovascular disease), 5 which may be exacerbated by cancer-related toxicities.
The long-term and late effects of cancer treatment, combined with the management of other chronic conditions, make cancer survivors particularly vulnerable to polypharmacy and its adverse effects. Polypharmacy, or taking multiple medications, may increase the risk of adverse drug events, financial toxicity, poor adherence, and drug-drug interactions. 6 Survivors often have multiple prescribing physicians (eg, an oncologist and primary care provider), 7 with prescriptions dispensed at several pharmacies. 8 Prescriptions for similar cancer-related treatment effects and chronic conditions may add duplicative, unnecessary drugs to medication regimens. Growing evidence has suggested that polypharmacy challenges the delivery of high-quality survivorship care, 1 but to the best of our knowledge the majority of studies to date [9] [10] [11] [12] have focused on older survivors or clinic-based samples. To our knowledge, little information exists regarding the burden of polypharmacy in cancer survivors across diverse health care settings.
In the current study, we examined polypharmacy and patterns of prescription medication use in a population-based sample of cancer survivors and adults without cancer. Specifically, we: 1) estimated the prevalence of polypharmacy and prescription expenditures; 2) characterized patterns of prescription medication use within therapeutic classes; and 3) identified patient-level factors associated with polypharmacy.
MATERIALS AND METHODS

Study Population
We used data from the Medical Expenditures Panel Survey (MEPS), a national survey that collects information regarding health care use and expenditures, health insurance, and health status from a representative sample of US households. Data are collected in an overlapping panel design; data for each panel are collected in 5 rounds of inperson interviews over an approximate 2-year period. We pooled data from 2008 through 2014, or overlapping panels 13 through 18.
Cancer survivors
We identified survey respondents (aged 18 years) who reported ever having been diagnosed with cancer. We matched cancer survivors with respondents reporting no history of cancer (hereafter referred to as "noncancer controls") by age (5-year intervals), sex, and survey year using a greedy matching algorithm without replacement, 13 with up to 4 noncancer controls for every survivor. Individuals reporting a diagnosis of nonmelanoma skin cancer only were eligible to be selected as a control.
Polypharmacy
MEPS respondents provide information regarding prescription medications, including the date of first fill, number of refills, and name and address of the pharmacy that filled each prescription. Pharmacies are contacted to supplement and verify responses, including data regarding drug type, dosage, quantity, and payment. Over the 2-year survey period, MEPS collected prescription data in rounds 1 and 3 of each panel. We defined polypharmacy as using 5 unique medications, a common measure used in geriatric populations. 10, 14 Prescription expenditures MEPS defines medical expenditures as the sum of direct payments for care provided during the survey year, including out-of-pocket payments and payments made by insurance and other sources. Prescription expenditures include amounts paid for prescriptions from all sources.
Statistical Analysis
Among both cancer survivors and noncancer controls, we described the median number of total medications (all fills and refills), unique medications, and total prescription expenditures. MEPS reports all prescriptions over a 2-year period as separate records for each respondent. We matched these prescription records to standard identifiers for generic drugs in RED BOOK (Truven Health Analytics, Ann Arbor, Michigan) and Medi-Span (Wolters Kluwer Health, Indianapolis, Indiana) to estimate the number of unique medications and avoid double counting medications differing only by quantity, dose, or manufacturer. From unique medications, we estimated the percentage of respondents prescribed 5 medications. Some respondents (8.4% of survivors and 10.5% of controls) dropped out in year 2, for whom data regarding total medications and total prescription expenditures are missing; however, we noted no significant differences in age and sex for respondents with missing versus complete prescription information.
To better understand common medication classes (eg, cardiovascular agents, metabolic agents), we examined the percentage of respondents prescribed medications within first-level, second-level, and third-level therapeutic classes and compared the percentages by time since diagnosis. We categorized survivors as "newly diagnosed" (diagnosed 1 year from the survey) or "previously diagnosed" (diagnosed >1 year from the survey). We focused on medication classes used to manage side effects from cancer treatment or long-term sequelae, such as antidepressants and anxiolytics. 15, 16 We determined therapeutic class using Multum Lexicon, 17 a 3-level nested category system that assigns a therapeutic class to each drug. For example, the first-level class "central nervous system agents" comprises second-level classes of analgesics, anxiolytics, and muscle relaxants, among others. We excluded panels 17 and 18 (4658 survivors) from the current analysis because MEPS did not collect the data needed to determine time since diagnosis.
Among cancer survivors, we used log binomial regression to identify patient-level factors associated with polypharmacy (5 unique medications). Herein, we have presented unadjusted and adjusted prevalence ratios and 95% confidence intervals (95% CIs).
In subgroup analyses, we estimated the prevalence of polypharmacy (5 unique medications) across categories of age and number of comorbidities for both survivors and controls.
We conducted sensitivity analyses: 1) excluding individuals newly diagnosed with cancer (diagnosed 1 year from the survey date; 962 individuals); 2) examining the prevalence of polypharmacy, total and unique medications, and total prescription expenditures by time since diagnosis; and 3) with alternate definitions of polypharmacy (eg, 3 or 7 unique prescriptions). These analyses did not change the direction or magnitude of the results. Therefore, we have reported the results of the primary analysis only. All analyses were conducted using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina). To account for the complex survey design, we used survey weights, sampling strata, and primary sampling units. The study was approved by the institutional review board at the University of Texas Southwestern Medical Center (#122016-060).
RESULTS
Compared with noncancer controls (19,588 controls), a higher percentage of cancer survivors (5216 survivors) were non-Hispanic white, unemployed, and covered by Medicaid or other public insurance ( Table 1 ). The prevalence of chronic conditions was higher among survivors compared with controls, with notable differences in the percentage of individuals reporting heart disease, hypercholesterolemia, and arthritis. A higher percentage of survivors reported 2 comorbid conditions, physical limitations, and fair or poor health status compared with controls. The majority of cancer survivors (55.0%) were diagnosed 5 years before the survey, and a similar percentage were diagnosed 1 year (21.4%) and 2 to 5 years (23.6%) prior. Cancers of the breast (21.2%), prostate (15.2%), and colon (7.4%) were the most common cancer types (data not shown).
Polypharmacy was more prevalent in cancer survivors compared with noncancer controls (Table 2) . Specifically, a higher percentage of survivors were prescribed 5 unique medications (64.0%; 95% CI, 62.3%-65.8%) compared with controls (51.5%; 95% CI, 50.4%-52.6%), and we observed a similar pattern in sensitivity analyses by time since diagnosis (see Supporting Table 1 ). With the exception of lung cancer (79.6%; 95% CI, 75.6%-83.7%), prevalence was found to be similar across cancer types (data not shown). Survivors also were prescribed a greater median number of total (35 vs 21) and unique (6 vs 4) medications. Median prescription expenditures were $1633 among cancer survivors and $784 among noncancer controls. In subgroup analyses ( prescribed 5 unique medications compared with 20.8% of noncancer controls. Across all therapeutic classes, a higher percentage of newly and previously diagnosed cancer survivors were prescribed medications compared with noncancer controls (Table 4) , with large differences observed for central nervous system, psychotherapeutic, cardiovascular, and gastrointestinal agents. The prevalence of opioid and narcotic analgesic use was more than double among newly diagnosed cancer survivors (43.0%; 95% CI, 39.3%-46.8%) compared with noncancer controls (21.2%; 95% CI, 20.3%-22.1%), and the prevalence was 28.6% (95% CI, 26.5%-30.6%) among previously diagnosed cancer survivors. This finding was similar in the subgroup of respondents with arthritis (see Supporting Table 2 ), in which both newly and previously diagnosed cancer survivors were prescribed more opioids compared with noncancer controls. A higher percentage of survivors also were prescribed benzodiazepines compared with controls, including combinations with opioids (Table 4) . Adjusted analyses of patient-level factors associated with polypharmacy demonstrated that cancer survivors with comorbid conditions, physical limitations, and good or fair/poor self-reported health (vs excellent/very good) had a higher prevalence of polypharmacy (Table 5) . Survivors who were uninsured (vs privately insured), unemployed, and non-Hispanic black or of other race/ethnicity had a lower prevalence of polypharmacy.
DISCUSSION
In a large, nationally representative sample of cancer survivors, we found a higher prevalence of all indicators of polypharmacy among survivors compared with adults without cancer. Survivors were prescribed more unique medications, 5 concurrent medications, and drugs with abuse potential. Cancer survivors also had substantially higher prescription expenditures compared with noncancer controls. These findings persisted across categories of age and number of comorbidities, and differences in polypharmacy between cancer survivors and noncancer Abbreviations: 95% CI, 95% confidence interval; NSAID, nonsteroidal anti-inflammatory drug. Time since diagnosis was estimated using age at the time of diagnosis reported during the round 1 interview, panels 13 to 16. a Diagnosis 1 year from the survey. b Diagnosis >1 year from the survey. c Antineoplastics among controls included anastrozole, letrozole, tamoxifen, raloxifene, and methotrexate.
controls were most striking in the youngest age groups and those with no comorbid conditions. Cancer survivors had more than double the cost of prescriptions, suggesting polypharmacy contributes to the growing costs 18, 19 of cancer treatment and survivorship care. Many patients with cancer and cancer survivors report symptoms of financial toxicity, 20 including devastating out-of-pocket spending, worry about medical bills, and medical debt or bankruptcy. Differences in cost for specialty versus nonspecialty drugs may drive higher prescription expenditures among survivors. Because specialty drugs play an increasingly important role in managing chronic conditions, 21 the economic burden of these drugs may persist for many years after a cancer diagnosis. 22 For example, newly and previously diagnosed cancer survivors in the current study were found to have similar prescription expenditures ($783 and $757, respectively, annually), both of which were higher than those of adults without cancer ($383 annually; data not shown). High medication costs may lead survivors to delay or discontinue refills, or to make changes in regimens to defray outof-pocket costs. 23, 24 Nearly twice as many cancer survivors were prescribed drugs with abuse potential, including benzodiazepines and opioids, compared with adults without cancer. Prescription patterns changed over the survivorship course, whereby a higher percentage of newly diagnosed survivors were prescribed these drugs than previously diagnosed survivors. Use tapered as time since diagnosis increased, but it remained markedly higher among both groups of cancer survivors compared with noncancer controls. We also observed no difference in nonsteroidal antiinflammatory drug use among survivors and controls, and, in the subgroup of respondents with arthritis, a condition for which treatment with narcotics might be expected, we still found a higher percentage of survivors who were prescribed opioids. Because the majority of survivors were diagnosed >5 years before the survey, these sensitivity and secondary analyses suggest that opioids may be used inappropriately to manage chronic pain, or may reflect fragmented care, 3 as survivors transition from active treatment to primary care. Prolonged use of these drugs is concerning given the increased risk of adverse psychological and physical effects, physical dependence, and withdrawal, 25, 26 particularly in light of the current opioid crisis in the United States. 27, 28 Younger and healthier cancer survivors used a similar number of medications as older adults without cancer. Specifically, survivors aged 18 to 39 years were found to have double the prevalence of polypharmacy compared with age-matched controls. Adolescent and young adult (AYA) cancer survivors comprise a unique, yet to our knowledge understudied, group in cancer research. 29, 30 AYA patients often receive fragmented care as they are caught between pediatric and adult oncology, 31 perhaps increasing the likelihood of polypharmacy and multiple prescribing physicians. Compared with older cancer survivors, AYA cancers survivors have earlier onset chronic conditions that accumulate over the life course. 32 Many AYA survivors report unmet health care needs, particularly for the late effects of treatment, 33 mental health, weight management, and pain management. 32 Financial challenges also may compromise adherence to multiple prescription regimens. 34 Despite the tendency to focus on polypharmacy and its consequences in older patients with cancer, [10] [11] [12] the findings of the current study call attention to AYA survivors as a priority population for future research.
Compared with noncancer controls, cancer survivors were more often prescribed psychotherapeutic, cardiovascular, and gastrointestinal agents. Similarly, we found chronic conditions, physical function, and health status were major drivers of polypharmacy in cancer survivors. Some medications used to manage comorbidities and late effects may be duplicative, such as those for treatment-induced cardiotoxicity and preexisting cardiovascular disease. Others, such as psychotherapeutic agents, may be added to medication regimens shortly after diagnosis and continued through survivorship. Cancer survivors can experience psychosocial distress (eg, fear, anxiety, sadness, and depression) related to or many years after a new diagnosis of cancer. [35] [36] [37] Last, survivors may have more opportunity to be prescribed medications because they visit multiple physicians for several different health conditions. 38, 39 MEPS respondents do not report prescription indication, a limitation common in pharmacoepidemiology research. 40 We could not determine the appropriateness of each medication, but studies regarding older cancer survivors have suggested that potentially inappropriate use is common 12, 41, 42 and increases in the year after diagnosis. 43 We did not capture over-the-counter medication or supplement use, potentially underestimating the prevalence of polypharmacy in cancer survivors. These limitations highlight the need for clinically annotated data, including indication and disease severity, to understand the impact of polypharmacy on cancer outcomes.
The results of the current study provide compelling evidence that cancer survivors experience an additional care burden from polypharmacy, and underscore the challenge of weighing the risks and benefits of specific medications within the context of a new or prior cancer diagnosis. Survivors may be at an increased risk of the numerous consequences of polypharmacy, including adverse drug events, financial toxicity, poor adherence, and drug-drug interactions.
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